The Food and Drug Administration seeks stakeholder input on how it might use Risk Evaluation and Mitigation Strategies to facilitate appropriate prescribing of opioid pain relievers. For example, the agency’s Opioid Policy Steering Committee is considering using REMS to require sponsors to ensure that opioid analgesic prescriptions exceeding a certain amount document medical necessity and/or leverage a nationwide prescription history database to prevent misuse or abuse, the FDA notice states. The agency will hold a Jan. 30 public hearing on the issue, with comments accepted through March 16.

Headline
An eighth Pennsylvania resident has died from measles, the state’s Department of Health announced Nov. 18. According to an update provided by the department…
Headline
The University of South Carolina Rural Health Research Center recently published a study examining differences in rural and urban child health across the…
Headline
An AHA blog published today responds to the Lown Institute’s latest report on hospital community benefits, saying that the report uses an “artificially narrow”…
Headline
The AHA Nov. 20 responded to a request for information from the Centers for Disease Control and Prevention on data intermediaries and ways to improve public…
Headline
The departments of Health and Human Services, Labor, and the Treasury Nov. 13 launched the Independent Dispute Resolution Gateway, a new centralized platform…
Blog
Public
The Lown Institute recently released its latest “Fair Share” report, which attempts to compare the value of nonprofit hospitals’ federal tax exemption with how…